Get Started
To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.
Get in Touch• 95% cell transfection efficiency
• No observed cytotoxicity
• Gene knockdown via siRNA expression
• in vitro and in vivo applications
• Non-viral transfection
Applications:
• siRNA transfection for gene knockdown via RNAi both in vitro and in vivo
Top Right: Enriched (>90%) E18 primary rat cortical neurons treated at DIV12 with Neuro9 siRNA against HPRT. HPRT mRNA assayed by qPCR 48h post-treatment. *** P < 0.001
Middle Right: Enriched (>90%) E18 primary rat cortical neurons treated at DIV7 with Neuro9 siRNA against HPRT for 48 hours. Cell viability assayed using PrestoBlue.
Bottom Right: Primary rat neurons were treated at various stages of maturity with Neuro9 siRNA against PTEN. Neuro9 is well tolerated and can be applied at DIV ≥ 2. This flexibility opens doors to new experimental possibilities. *** P < 0.001
Images: Fluorescently labeled Neuro9 (red) is used to observe uptake by MAP2+ neurons (green).
Plot: Flow cytometry indicates Neuro9 uptake in >95% of cells
Kit Type | Encapsulates | Treats (wells of 24 well plate) | |
siRNA | 2 nmol (2x) | 50 | NWS0001 |
siRNA | 5 nmol | 100 | NWS0002 |
Kit Type | Encapsulates | Treats (wells of 24 well plate) | |
siRNA | 0.5 mg | 15 | NWT0001 |
siRNA | 2 mg | 20 | NWT0002 |
To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.
Get in TouchPublication - Abstract
July 01, 2020
Journal of Controlled Release
Publication - Abstract
May 08, 2020
Vaccines
Publication - Abstract
April 02, 2020
Journal of Controlled Release
Publication - Abstract
December 31, 2019
Vaccines
Publication - Abstract
May 31, 2019
Vaccine